Lowest Price Guaranteed
Slides
198
Last Updated
September 2026
View Count
3164
1. PREFACE
1.1. Introduction
1.2. Market Key Insights
1.3. Market Segmentation
1.4. Market Share Insights
1.5. Key Questions Answered
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion
5. EXECUTIVE SUMMARY
5.1. Chapter Overview
5.2. Executive Summary: North America Antibody-Drug Conjugates Market Landscape
5.3. Executive Summary: North America Antibody-Drug Conjugates Market Trends
5.4. Executive Summary: North America Market Forecast and Opportunity Analysis
6. INTRODUCTION
6.1. Chapter Overview
6.2. Pillars of Cancer Therapy
6.3. Antibody-drug Conjugates
6.3.1. History of Antibody-Drug Conjugates
6.3.2. Differences Between Small Molecule Drugs, Monoclonal Antibody Therapies and Antibody-Drug Conjugates
6.3.3. Components of Antibody-Drug Conjugates
6.3.3.1. Antibody
6.3.3.2. Cytotoxin
6.3.3.3. Linker
6.3.4. Advantages of Antibody-Drug Conjugates Over Traditional Therapeutics
6.3.5. Pharmacokinetic Properties of Antibody-Drug Conjugates
6.3.5.1. Absorption
6.3.5.2. Distribution
6.3.5.3. Metabolism and Elimination
6.4. Concluding Remarks
7. MARKET LANDSCAPE
7.1. Chapter Overview
7.2. North America Antibody-Drug Conjugates: Overall Market Landscape
7.2.1. Analysis by Stage of Development
7.2.2. Analysis by Target Indication
7.2.3. Analysis by Therapeutic Area
7.2.4. Analysis by Line of Treatment
7.2.5. Analysis by Dosing Frequency
7.2.6. Analysis by Type of Therapy
7.2.7. Analysis by Target Antigen
7.2.8. Analysis by Antibody Isotypes
7.2.9. Analysis by Type of Linker
7.2.10. Analysis by Payload / Cytotoxin / Warhead
7.2.11. Analysis by Type of Payload
7.3. North America Antibody-Drug Conjugate Developers: Overall Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
7.3.4. Most Active Player: Analysis by Number of Therapies
8. TARGET COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Key Parameters and Scoring Criteria
8.3. Methodology
8.4. North America Antibody-Drug Conjugates: Target Competitiveness Analysis
8.4.1. Three-Dimensional Bubble Analysis
8.4.1.1. Targets of Approved / Marketed Drugs
8.4.1.2. Targets of Phase III Drugs
8.4.1.3. Targets of Phase II Drugs
8.4.1.4. Targets of Phase I Drugs
8.4.1.5. Targets of Preclinical Stage Drugs
8.4.2. Six-Dimensional Spider Web Analysis
9. COMPANY PROFILES
9.1. Chapter Overview
9.2. AbbVie
9.2.1. Company Overview
9.2.2. Antibody-Drug Conjugates Pipeline
9.2.3. Recent Developments and Future Outlook
9.3. BeOne Medicines
9.4. Elevation Oncology
9.5. Eli Lilly and Company
9.6. Gilead Sciences
9.7. Immunome
10. CLINICAL TRIAL ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. North America Antibody Drug Conjugates: Clinical Trial Analysis
10.3.1. Analysis by Trial Registration Year
10.3.2. Analysis of Number of Patients Enrolled by Trial Registration Year
10.3.3. Analysis by Trial Phase
10.3.4. Analysis of Number of Patients Enrolled by Trial Phase
10.3.5. Analysis by Trial Status
10.3.6. Analysis by Trial Registration Year and Trial Status
10.3.7. Analysis of Number of Patients Enrolled by Trial Status
10.3.8. Analysis by Patient Gender
10.3.9. Analysis by Study Design
10.3.9.1. Analysis by Type of Allocation
10.3.9.2. Analysis by Type of Intervention Model
10.3.9.3. Analysis by Type of Masking
10.3.9.4. Analysis by Trial Purpose
10.3.10. Analysis by Type of Sponsor / Collaborator
10.3.11. Leading Industry Players: Analysis by Number of Clinical Trials
10.3.12. Leading Non-Industry Players: Analysis by Number of Clinical Trials
10.3.12.1. Analysis by Geography
10.3.12.2. Analysis of Clinical Trials by Geography
10.3.12.3. Analysis of Clinical Trials by Geography and Trial Status
10.3.12.4. Analysis of Patients Enrolled by Geography and Trial Status
11. KEY OPINION LEADERS
11.1. Chapter Overview
11.2. Assumption and Key Parameters
11.3. Methodology
11.4. Antibody Drug Conjugates: Key Opinion Leaders
11.4.1. Analysis by Role of KOLs
11.4.2. Analysis by Qualification
11.4.3. Analysis by Type of Organization
11.4.4. Analysis by Affiliated Organization
11.4.5. Analysis by Geographical Location of KOLs
11.4.6. Analysis by Target Indication
11.4.7. Most Prominent KOLs: Analysis by KOLs Expertise, Activeness and Strength
11.4.8. Most Prominent KOLs: Analysis by Roots Analysis (RA) Score
11.4.9. Most Prominent KOLs: Comparison of RA Score and Third-Party Score
12. PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Partnership Models
12.3. North America Antibody Drug Conjugates Market: Partnerships and Collaborations
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by Year and Type of Partnership
12.3.4. Analysis by Type of Partner
12.3.5. Most Active Players: Analysis by Number of Partnerships
12.3.6. Analysis by Geography
12.3.6.1. Analysis by Country
12.3.6.2. Analysis by Continent
13. FUNDING AND INVESTMENT ANALYSIS
13.1. Chapter Overview
13.2. Funding Models
13.3. North America Antibody Drug Conjugates Market: Funding and Investment Analysis
13.3.1. Analysis by Year of Funding
13.3.1.1. Cumulative Year-wise Trend of Funding Instances
13.3.1.2. Cumulative Year-wise Trend of Amount Invested
13.3.2. Analysis by Type of Funding
13.3.2.1. Analysis of Funding Instances
13.3.2.2. Analysis of Amount Invested
13.3.3. Analysis of Amount Invested by Year and Type of Funding
13.3.4. Analysis by Geography
13.3.5. Most Active Players
13.3.5.1. Analysis by Number of Funding Instances
13.3.5.2. Analysis by Amount Raised
14. PATENT ANALYSIS
14.1. Chapter Overview
14.2. Scope And Methodology
14.3. North America Antibody Drug Conjugates: Patent Analysis
14.3.1. Analysis by Patent Publication Year
14.3.2. Analysis by Type of Patent and Publication Year
14.3.3. Analysis by Patent Application Year
14.3.4. Analysis by Patent Jurisdiction
14.3.5. Analysis by CPC Symbols
14.3.6. Analysis by Type of Applicant
14.3.7. Leading Industry Players: Analysis by Number of Patents
14.3.8. Leading Non-Industry Players: Analysis by Number of Patents
14.4. Patent Benchmarking Analysis
14.4.1. Analysis by Patent Characteristics
14.5. Patent Valuation
14.6. Leading Patents by Number of Citations
15. GRANTS ANALYSIS
15.1. Chapter Overview
15.2. Scope and Methodology
15.3. North America Antibody Drug Conjugates: Grants Analysis
15.3.1. Analysis by Year of Grant Awarded
15.3.2. Analysis by Amount Awarded
15.3.3. Analysis by Funding Institute Center
15.3.4. Analysis by Support Period
15.3.5. Analysis by Type of Grant Application
15.3.6. Analysis by Purpose of Grant Award
15.3.7. Analysis by Activity Code
15.3.8. Analysis by Study Section Involved
15.3.9. Popular NIH Departments: Analysis by Number of Grants
15.3.10. Prominent Program Officers: Analysis by Number of Grants
15.3.11. Popular Recipient Organizations: Analysis by Number of Grants
15.3.12. Popular Recipient Organizations: Analysis by Grant Amount
15.3.13. Analysis by Region of Recipient Organization
16. KEY COMMERCIALIZATION STRATEGIES
16.1. Chapter Overview
16.2. Successful Drug Launch Strategy: ROOTS Framework
16.3. Successful Drug Launch Strategy: Product Differentiation
16.4. Common Commercialization Strategies Adopted Across Different Stages of Product Development
16.5. Key Commercialization Strategies Adopted by the Companies Focused on North America Antibody Drug Conjugates
16.5.1. Participation in the Global Events
16.5.2. Collaboration with External Stakeholders and Pharmaceutical Firms
16.5.3. Geographical Expansion
16.5.4. Awareness Through Product Website
16.6. Concluding Remarks
17. NOVEL CONJUGATION AND LINKER TECHNOLOGY PLATFORMS
17.1. Chapter Overview
17.2. North America Antibody Drug Conjugates: Conjugation Technologies
17.2.1. Chemical Conjugation
17.2.2. Enzymatic Conjugation
17.3. North America Antibody Drug Conjugates: List of Conjugation Technologies
17.4. North America Antibody Drug Conjugates: Linker Technologies
17.4.1. Non-cleavable Linkers
17.4.2. Cleavable Linker
17.5. North America Antibody Drug Conjugates: List of Linker and Linker-Payload Technologies
17.6. Concluding Remarks
18. ASSESSMENT OF ADCS NON-CLINICAL DATA: FOCUS ON FIRST IN HUMAN DOSING
18.1. Chapter Overview
18.2. North America Antibody Drug Conjugates and Non-Clinical Studies
18.3. ICH S9 Guideline
18.4. Investigational New Drug (IND)-Enabling Study Designs
18.4.1. Example Case: Kadcyla
18.5. Toxicities in Animal Models
18.6. Prediction of Maximum Tolerated Dosage (MTD) in Humans
18.7. Other Key Considerations for Study Design
19. COST PRICE ANALYSIS
19.1. Chapter Overview
19.2. Factors Contributing Towards the High Price of North America Antibody Drug Conjugates
19.3. North America Antibody Drug Conjugates Market: Cost Price Analysis
19.3.1. On the Basis of Associated Costs
19.3.2. On the Basis of Competition
19.3.3. On the Basis of Patient Segment
19.4. Reimbursement Considerations for North America Antibody Drug Conjugates
20. CASE STUDY 1: CONTRACT MANUFACTURING OF NORTH AMERICA ANTIBODY DRUG CONJUGATES
20.1. Chapter Overview
20.2. Key Steps for Antibody-Drug Conjugate Manufacturing
20.3. Technical Challenges Related to North America Antibody Drug Conjugates Manufacturing
20.4. Challenges Associated with Supply Chain and Method Transfer
20.5. Limitation of In-House Manufacturing
20.6. Investments in Antibody-Drug Conjugate Manufacturing Capability Expansions
20.7. Collaborations Established for North America Antibody Drug Conjugates Manufacturing
20.8. Growing Demand for Contract Manufacturing
20.9. CMOs with Linker Manufacturing Capabilities
20.10. CMOs with HPAPI / Cytotoxic Payload Manufacturing Capabilities
20.11. CMOs with Conjugation Capabilities
20.12. North America Antibody Drug Conjugates One-Stop-Shops
20.13. Increasing Demand for One-Stop-Shops
21. CASE STUDY 2: COMPANION DIAGNOSTICS FOR NORTH AMERICA ANTIBODY DRUG CONJUGATES
21.1. Chapter Overview
21.1.1. Advantages of Companion Diagnostics
21.1.2. Challenges Associated with the Development of Companion Diagnostics
21.2. Companion Diagnostics for North America Antibody Drug Conjugates
21.3. Companion Diagnostics for Antibody Therapeutics
21.3.1. Analysis by Type of Cancer
21.3.2. Most Prominent Players: Analysis by Number of Tests
22. SWOT ANALYSIS
22.1. Chapter Overview
22.2. Strengths
22.2.1. Improved Safety and Patient Adherence
22.2.2. Rise of Next-Generation Conjugation Technologies
22.2.3. Robust Pipeline with Multiple Late-Stage Product Candidates
22.2.4. Growing Involvement of the Academic Institute
22.3. Weaknesses
22.3.1. Technical Complexities Associated with Product Development
22.3.2. Manufacturing, Logistics and Supply Chain Challenges
22.3.3. Batch to Batch Inconsistency
22.4. Opportunities
22.4.1. Increasing Collaboration and Venture Capital Funding
22.4.2. Expanding Therapeutics Reach
22.4.3. Life Cycle Management
22.4.4. Combination Therapies
22.4.5. Opportunities for CMOs
22.5. Threats
22.5.1. Failure of Clinical / Marketed Candidates
22.5.2. Increased Competition from Other Therapeutic Classes
23. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. North America Antibody Drug Conjugates Market: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
23.3.1. Scenario Analysis
23.3.1.1. Conservative Scenario
23.3.1.2. Optimistic Scenario
23.4. Key Market Segmentations
24. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET, BY TARGET INDICATION
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. North America Antibody Drug Conjugates Market: Distribution by Type of Target Indication
24.3.1. North America Antibody Drug Conjugates Market for Breast Cancer, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
24.3.2. North America Antibody Drug Conjugates Market for Non-Small Cell Lung Cancer, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
24.3.3. North America Antibody Drug Conjugates Market for Ovarian Cancer, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
24.3.4. North America Antibody Drug Conjugates Market for Multiple Myeloma, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
24.3.5. North America Antibody Drug Conjugates Market for B-Cell Lymphoma, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
24.3.6. North America Antibody Drug Conjugates Market for Renal Cancer, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
24.3.7. North America Antibody Drug Conjugates Market for Gastric Cancer, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
24.3.8. North America Antibody Drug Conjugates Market for Head and Neck Cancer, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
24.3.9. North America Antibody Drug Conjugates Market for Hodgkin's Lymphoma, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
24.3.10. North America Antibody Drug Conjugates Market for T-Cell Lymphoma, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
24.3.11. North America Antibody Drug Conjugates Market for Other Target Indications, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
24.4. Data Triangulation and Validation
25. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET, BY THERAPEUTIC AREA
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. North America Antibody Drug Conjugates Market: Distribution by Therapeutic Area
25.3.1. North America Antibody Drug Conjugates Market for Solid Tumor, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
25.3.2. North America Antibody Drug Conjugates Market for Hematological Cancer, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
25.4. Data Triangulation and Validation
26. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET, BY TYPE OF ANTIBODY
26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. North America Antibody Drug Conjugates Market: Distribution by Type of Antibody
26.3.1. North America Antibody Drug Conjugates Market for Humanized, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
26.3.2. North America Antibody Drug Conjugates Market for Human, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
26.3.3. North America Antibody Drug Conjugates Market for Chimeric, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
26.4. Data Triangulation and Validation
27. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET, BY TARGET ANTIGEN
27.1. Chapter Overview
27.2. Key Assumptions and Methodology
27.3. North America Antibody Drug Conjugates Market: Distribution by Target Antigen
27.3.1. North America Antibody Drug Conjugates Market for HER-2 (ERBB2), Historical Trends (since 2023) and Forecasted Estimates (till 2035)
27.3.2. North America Antibody Drug Conjugates Market for FOLR1 (Folate receptor alpha), Historical Trends (since 2023) and Forecasted Estimates (till 2035)
27.3.3. North America Antibody Drug Conjugates Market for TROP-2, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
27.3.4. North America Antibody Drug Conjugates Market for CD79b, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
27.3.5. North America Antibody Drug Conjugates Market for BCMA (TNFRSF17 / BCM), Historical Trends (since 2023) and Forecasted Estimates (till 2035)
27.3.6. North America Antibody Drug Conjugates Market for Nectin 4, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
27.3.7. North America Antibody Drug Conjugates Market for c-MET, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
27.3.8. North America Antibody Drug Conjugates Market for PD-L1, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
27.3.9. North America Antibody Drug Conjugates Market for CD30, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
27.3.10. North America Antibody Drug Conjugates Market for Other Antigens, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
27.4. Data Triangulation and Validation
28. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET, BY LINKER
28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. North America Antibody Drug Conjugates Market: Distribution by Linker
28.3.1. North America Antibody Drug Conjugates Market for Valine-citrulline, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
28.3.2. North America Antibody Drug Conjugates Market for Tetrapeptide-based Linker, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
28.3.3. North America Antibody Drug Conjugates Market for Maleimidocaproyl, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
28.3.4. North America Antibody Drug Conjugates Market for Succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
28.3.5. North America Antibody Drug Conjugates Market for Dipeptide Linker, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
28.3.6. North America Antibody Drug Conjugates Market for Peptide Linker, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
28.3.7. North America Antibody Drug Conjugates Market for Valine-alanine, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
28.3.8. North America Antibody Drug Conjugates Market for N-Succinimidyl 4-(2-pyridyldithio)-2-sulfobutanoate (Sulfo-SPDB), Historical Trends (since 2023) and Forecasted Estimates (till 2035)
28.3.9. North America Antibody Drug Conjugates Market for Maleimide, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
28.3.10. North America Antibody Drug Conjugates Market for Other Linkers, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
28.4. Data Triangulation and Validation
29. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD / CYTOTOXIN / WARHEAD
29.1. Chapter Overview
29.2. Key Assumptions and Methodology
29.3. North America Antibody Drug Conjugates Market: Distribution by Payload / Cytotoxin / Warhead
29.3.1. North America Antibody Drug Conjugates Market for Monomethyl auristatin E (MMAE), Historical Trends (since 2023) and Forecasted Estimates (till 2035)
29.3.2. North America Antibody Drug Conjugates Market for Camptothecin, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
29.3.3. North America Antibody Drug Conjugates Market for Exatecan, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
29.3.4. North America Antibody Drug Conjugates Market for Monomethyl auristatin F (MMAF), Historical Trends (since 2023) and Forecasted Estimates (till 2035)
29.3.5. North America Antibody Drug Conjugates Market for DM1, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
29.3.6. North America Antibody Drug Conjugates Market for DM4, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
29.3.7. North America Antibody Drug Conjugates Market for SN-38 / Irinotecan, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
29.3.8. North America Antibody Drug Conjugates Market for Other Payloads / Cytotoxins, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
29.4. Data Triangulation and Validation
30. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET, BY TYPE OF PAYLOAD
30.1. Chapter Overview
30.2. Key Assumptions and Methodology
30.3. North America Antibody Drug Conjugates Market: Distribution by Type of Payload
30.3.1. North America Antibody Drug Conjugates Market for Auristatin, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
30.3.2. North America Antibody Drug Conjugates Market for Topoisomerase I Inhibitors, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
30.3.3. North America Antibody Drug Conjugates Market for Exatecan Derivative Topoisomerase I Inhibitor, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
30.3.4. North America Antibody Drug Conjugates Market for Maytansinoid, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
30.3.5. North America Antibody Drug Conjugates Market for Camptothecin, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
30.3.6. North America Antibody Drug Conjugates Market for Other Types of Payloads, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
31. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET, BY COUNTRY
31.1. Chapter Overview
31.2. Key Assumptions and Methodology
31.3. North America Antibody Drug Conjugates Market: Distribution by Country
31.3.1. North America Antibody Drug Conjugates Market in the US, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
31.3.2. North America Antibody Drug Conjugates Market in Canada, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
32. CONCLUDING INSIGHTS
32.1. Chapter Overview
32.2. Concluding Insights: North America Antibody Drug Conjugates Market Landscape
32.3. Concluding Insights: North America Antibody Drug Conjugates Market Trends
32.4. Concluding Insights: North America Market Forecast and Opportunity Analysis
33. INSIGHTS FROM PRIMARY RESEARCH
33.1. Chapter Overview
33.2. Company A
33.2.1. Company Snapshot
33.2.2. Interview Transcript: Founder and Chief Executive Officer
33.3. Company B
33.3.1. Company Snapshot
33.3.2. Interview Transcript: Founder and Chief Executive Officer
33.4. Company C
33.4.1. Company Snapshot
33.4.2. Interview Transcript: Founder and Chief Executive Officer
33.5. Company D
33.5.1. Company Snapshot
33.5.2. Interview Transcript: Co-Founder and Chief Executive Officer
33.6. Company E
33.6.1. Company Snapshot
33.6.2. Interview Transcript: President and Executive Officer
33.7. Company F
33.7.1. Company Snapshot
33.7.2. Interview Transcript: Former Chief Executive Officer
33.8. Company G
33.8.1. Company Snapshot
33.8.2. Interview Transcript: President and Executive Director
33.9. Company H
33.9.1. Company Snapshot
33.9.2. Interview Transcript: Executive Director and Chief Scientific Officer
33.10. Company I
33.10.1. Company Snapshot
33.10.2. Interview Transcript: Former Chief Business Officer and Head of Strategy
33.11. Company J
33.11.1. Company Snapshot
33.11.2. Interview Transcript: Chief Commercial Officer
33.12. Company K
33.12.1. Company Snapshot
33.12.2. Interview Transcript: Chief Business Officer
33.13. Company L
33.13.1. Company Snapshot
33.13.2. Interview Transcript: Former Chief Business Officer
33.14. Company M
33.14.1. Company Snapshot
33.14.2. Interview Transcript: Former Vice President, Business Development
33.15. Company N
33.15.1. Company Snapshot
33.15.2. Interview Transcript: Former Vice President and Head of Chemistry
33.16. Company O
33.16.1. Company Snapshot
33.16.2. Interview Transcript: Director, Business Development
33.17. Company P
33.17.1. Company Snapshot
33.17.2. Interview Transcript: General Manager
33.18. Company Q
33.18.1. Company Snapshot
33.18.2. Interview Transcript: Former Director of CDMO
33.19. Company R
33.19.1. Company Snapshot
33.19.2. Interview Transcript: Former Director
33.20. Company S
33.20.1. Company Snapshot
33.20.2. Interview Transcript: Former Group Product Manager
33.21. Company T
33.21.1. Company Snapshot
33.21.2. Interview Transcript: Former Head of Bioconjugates Commercial Development
33.22. Company U
33.22.1. Company Snapshot
33.22.2. Interview Transcript: Former Site Head
33.23. Company V
33.23.1. Company Snapshot
33.23.2. Interview Transcript: Professor, School of Medicine
33.24. Company W
33.24.1. Company Snapshot
33.24.2. Interview Transcript: President and Chief Executive Officer
33.25. Company X
33.25.1. Company Snapshot
33.25.2. Interview Transcript: Chief Executive Officer and Co-founder
33.26. Company Y
33.26.1. Company Snapshot
33.26.2. Interview Transcript: Chief Executive Officer and Co-founder
33.27. Company Z
33.27.1. Company Snapshot
33.27.2. Interview Transcript: Founder and Chief Technology Officer
33.28. Company AA
33.28.1. Company Snapshot
33.28.2. Interview Transcript: Chief Executive Officer
33.29. Company AB
33.29.1. Company Snapshot
33.29.2. Interview Transcript: Chief Executive Officer
33.30. Company AC
33.30.1. Company Snapshot
33.30.2. Interview Transcript: President and Co-founder
33.31. Company AD
33.31.1. Company Snapshot
33.31.2. Interview Transcript: Vice President of Cell Technology
33.32. Company AE
33.32.1. Company Snapshot
33.32.2. Interview Transcript: Associate Director, Regulatory Affairs
33.33. Company AF
33.33.1. Company Snapshot
33.33.2. Interview Transcript: Team Leader, Research and Development
34. APPENDIX I: TABULATED DATA
35. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS